UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2014
MEI Pharma, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-50484 | | 51-0407811 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
11975 El Camino Real, Suite 101, San Diego, California 92130
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (858) 792-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 8, 2014, MEI Pharma, Inc. (the “Company”), conducted an Analyst and Investor Event at which Dr. Robert D. Mass presented a clinical update along with a presentation by Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center. A webcast of the presentation is available at www.meipharma.com.
A copy of the slides which accompanied the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Slides Presented at Analyst and Investor Event |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| MEI PHARMA, INC. |
| |
| By: | | /s/ Daniel P. Gold |
| | Daniel P. Gold |
| | Chief Executive Officer |
Dated: December 8, 2014
Index to Exhibits
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Slides Presented at Analyst and Investor Event |
